Amarin Corp Plc (AMRN)

[staccani]

As time goes by , to me it appears clearer and clearer that Vascepa should target many more indications and patients than the High Trigs patients on statins. In fact that population might not be the one in which EPA is more effective, although I expect to see a significant RRR also in the RIT population.

A huge amount of scientific literature has been accumulating on EPA much higher efficacy in reducing CVD death risk linked to chronic disease (heart/kidney failure, Infartcuated patients , liver cancer etc) and I bet many other diseases could be targeted by EPA such as liver disease, IPF, etc etc where inflammation plays a central role in the fibrogenetic process. My bet is that reducing inflammation also fibrogenesis will be slowed or maybe even reversed.
Fibrosis is thought to cause 1/3 of global deaths in the world. So if we add CVD and Cancer, we basically cover ca 90% of all deaths.
Do we know if EPA has been tested in any fibrotic condition so far?